Omnicell, Inc.
Fundamentals are temporarily unavailable for OMCL.
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.30B | $1.15B | $1.11B | $1.18B |
| Cost of Revenue | $706.96M | $650.27M | $641.24M | $681.40M |
| Gross Profit | $588.99M | $496.84M | $471.00M | $503.44M |
| Research & Development | $104.97M | $97.11M | $90.41M | $88.67M |
| Selling, General & Admin | $486.34M | $434.59M | $380.25M | $409.61M |
| Operating Expenses | $591.31M | $531.71M | $470.67M | $498.28M |
| Operating Income | -$2.32M | -$34.87M | $337.00K | $5.16M |
| EBITDA | $96.85M | $60.69M | $90.09M | $91.79M |
| Pretax Income | -$2.45M | -$20.11M | $25.59M | $11.32M |
| Income Tax | -$8.10M | $263.00K | $13.06M | $9.27M |
| Net Income | $5.65M | -$20.37M | $12.53M | $2.05M |
| Diluted EPS | 0.12 | -0.45 | 0.27 | 0.04 |
| Diluted Shares | 45.89M | 45.21M | 46.26M | 46.36M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & Equivalents | $330.36M | $467.97M | $369.20M | $196.52M |
| Receivables | $299.47M | $252.03M | $256.40M | $216.86M |
| Inventory | $147.55M | $110.10M | $88.66M | $100.91M |
| Current Assets | $881.81M | $927.57M | $815.49M | $680.07M |
| Total Assets | $2.21B | $2.23B | $2.12B | $1.97B |
| Current Liabilities | $428.45M | $367.79M | $595.68M | $476.61M |
| Long-Term Debt | $566.57M | $569.66M | $166.40M | $167.60M |
| Total Debt | $616.74M | $614.09M | $382.55M | $204.34M |
| Total Liabilities | $1.08B | $1.04B | $877.65M | $742.91M |
| Retained Earnings | $390.73M | $370.36M | $382.89M | $384.94M |
| Shareholders' Equity | $1.13B | $1.19B | $1.24B | $1.23B |
| Working Capital | $453.37M | $559.78M | $219.81M | $203.46M |
| Net Debt | $236.21M | $101.69M | — | — |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | $77.78M | $181.09M | $187.72M | $127.30M |
| Capital Expenditure | -$60.74M | -$55.02M | -$52.79M | -$57.93M |
| Free Cash Flow | $17.04M | $126.08M | $134.93M | $69.37M |
| Depreciation & Amortisation | $99.17M | $95.56M | $89.75M | $86.63M |
| Stock-Based Compensation | $68.25M | $55.30M | $39.32M | $44.50M |
| Investing Cash Flow | -$58.67M | -$55.02M | -$52.79M | -$60.36M |
| Financing Cash Flow | -$20.95M | $23.42M | -$235.58M | -$218.32M |
| Share Repurchases | -$52.21M | $0.00 | $0.00 | -$77.60M |
| Net Change in Cash | -$1.84M | $149.50M | -$100.65M | -$151.38M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Revenue | $269.67M | $290.56M | $310.63M | $313.98M | $309.88M | $312.21M |
| Cost of Revenue | $158.73M | $162.88M | $176.13M | $183.66M | $169.52M | $159.27M |
| Gross Profit | $110.94M | $127.68M | $134.50M | $130.32M | $140.36M | $152.94M |
| Research & Development | $20.53M | $21.57M | $24.02M | $22.55M | $21.52M | $20.30M |
| Selling, General & Admin | $102.03M | $97.98M | $102.24M | $107.36M | $101.99M | $100.19M |
| Operating Expenses | $122.56M | $119.56M | $126.26M | $129.91M | $123.51M | $120.49M |
| Operating Income | -$11.62M | $8.12M | $8.24M | $415.00K | $16.85M | $32.45M |
| EBITDA | $10.22M | $29.77M | $29.61M | $22.20M | $37.35M | $53.19M |
| Pretax Income | -$9.53M | $10.45M | $9.70M | $699.00K | $16.91M | $33.83M |
| Income Tax | -$2.51M | $4.81M | $4.24M | $2.73M | $5.55M | $9.54M |
| Net Income | -$7.02M | $5.64M | $5.46M | -$2.03M | $11.36M | $24.29M |
| Diluted EPS | -0.15 | 0.12 | 0.12 | -0.05 | 0.25 | 0.52 |
| Diluted Shares | 46.60M | 46.99M | 45.90M | 44.96M | 45.94M | 46.30M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $386.83M | $399.00M | $180.05M | $196.52M | $239.22M | $292.17M |
| Receivables | $251.60M | $232.68M | $245.72M | $216.86M | $249.80M | $227.05M |
| Inventory | $91.14M | $105.78M | $107.43M | $100.91M | $99.20M | $96.72M |
| Current Assets | $839.67M | $844.78M | $659.62M | $680.07M | $722.30M | $735.39M |
| Total Assets | $2.15B | $2.15B | $1.95B | $1.97B | $2.00B | $2.00B |
| Current Liabilities | $607.53M | $594.39M | $456.59M | $476.61M | $483.05M | $447.44M |
| Long-Term Debt | $166.70M | $166.99M | $167.29M | $167.60M | $167.90M | $168.20M |
| Total Debt | $385.83M | $384.41M | $206.78M | $204.34M | $202.18M | $200.00M |
| Total Liabilities | $894.37M | $881.88M | $727.70M | $742.91M | $747.48M | $707.25M |
| Retained Earnings | $375.87M | $381.50M | $386.97M | $384.94M | $396.30M | $420.59M |
| Shareholders' Equity | $1.26B | $1.26B | $1.22B | $1.23B | $1.26B | $1.29B |
| Working Capital | $232.13M | $250.38M | $203.03M | $203.46M | $239.25M | $287.94M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $25.92M | $42.76M | $28.27M | $30.35M | $54.50M | $68.31M |
| Capital Expenditure | -$15.74M | -$15.92M | -$14.28M | -$11.99M | -$15.87M | -$12.53M |
| Free Cash Flow | $10.19M | $26.83M | $13.99M | $18.36M | $38.63M | $55.78M |
| Depreciation & Amortisation | $21.84M | $21.65M | $21.36M | $21.78M | $20.50M | $20.75M |
| Stock-Based Compensation | $10.79M | $10.53M | $11.21M | $11.98M | $9.50M | $12.21M |
| Investing Cash Flow | -$15.74M | -$15.92M | -$14.28M | -$14.42M | -$15.87M | -$12.53M |
| Financing Cash Flow | $4.04M | -$11.47M | -$219.98M | $9.10M | $2.39M | -$23.38M |
| Share Repurchases | — | — | -$61.95M | $0.00 | — | — |
| Net Change in Cash | $14.22M | $15.36M | -$206.00M | $25.03M | $41.02M | $32.41M |
Market Snapshot
About
Omnicell provides automation and analytics solutions for hospital medication management. The company's products include automated dispensing cabinets, IV compounding robots, medication adherence packaging, and inventory management software. Omnicell's systems help hospitals reduce medication errors, control costs, and improve workflow efficiency.